FDA has approved Novartis' Ilaris to treat a rare, genetic autoinflammatory disease, reports the Wall Street Journal. The paper's Health Blog adds that Ilaris is an example of that prized goal, personalized medicine. "It's also the first concrete result of Novartis's seven-year effort to target the genetic causes of disease.